2022 AABB Virtual Annual Meeting

Nov 5, 2022 ‐ Nov 7, 2022



Sessions

AM22-02-L: Under-Recognized Complications of Transfusion (Internet Live)

Nov 6, 2022 11:15am ‐ Nov 6, 2022 12:15pm

Identification: AM22-02-L

Credits: None available.

Although a variety of strategies ranging from donor screening to compatibility testing and patient monitoring during hemotherapy (HT) exist to decrease transfusion complications, transfusion associated adverse events(TAAEs) can go undetected. Hemovigilance measures have been developed to capture many transfusion complications, however, even with these approaches, some adverse transfusion outcomes can occur days to weeks following HT, potentially compromising their detection. Two entities particularly challenging in this regard are delayed hemolytic transfusion reactions (DHTRs) and hyperhemolysis. Transfusion associated hyperkalemia (TAH), another potentially life-threatening rare complication of RBC transfusion may lead to severe cardiac comprise in patients and represents an TAAE that may have a particularly profound impact in pediatric patients. In this session we will explore common clinical presentations and pathophysiological mechanisms of DHTRs by examining the workup, diagnosis, transfusion support and management of DHTRs and hyperhemolysis. With respect to TAH we will explore its prevalence, characteristics of patients at particular risk, its morbidity and mortality, as well as the features of the blood units themselves and their associated infusion practices. Finally, we will highlight emerging opportunities to improve hemovigilance practices to capture these under-appreciated entities and potentially aid in their mitigation.

Learning Objectives:
  • Demonstrate that Delayed Hemolytic Transfusion Reactions (DHTRs) can occur in the absence of detectable alloantibodies and describe clinical and laboratory findings that support and differentiate the diagnoses of DHTRs and hyperhemolysis along with their respective managements
  • Describe various facets of Transfusion Associated Hyperkalemia (TAH) including its prevalence, diagnosis, and management
  • Identify gaps and barriers in the diagnosis and reporting of these under-recognized complications of hemotherapy that may help to inform and enhance hemovigilance monitoring systems
Moderator(s): Speaker(s):
  • Dr. Sean Stowell, MD, PhD, Brigham and Women's Hospital Apheresis Service Associate Medical Director, Brigham and Women's Hospital
  • Chisa Yamada, MD, University of Michigan
Disclosures
  • Chester Andrzejewski, Jr., PhD,MD,FCAP : IBM: Subcontractor as prime contractor on FDA, CBER and BEST initiative
  • Sean Stowell, MD, PhD : Grifols, Alexion, Cellics, Argenx, Novartis: Consultant
  • Chisa Yamada, MD : Nothing to disclose.

AM22-03-L: Ethical Considerations in Blood Supply Management During Critical Blood Shortages (Internet Live)

Nov 6, 2022 11:15am ‐ Nov 6, 2022 12:15pm

Identification: AM22-03-L

Credits: None available.

The COVID-19 pandemic has created many challenges across the healthcare system. The greatest impact to transfusion medicine has been the ability to maintain a healthy blood supply across the nation and an imbalance between the supply of blood components and the demand to meet patient needs. The recent and ongoing severe blood shortage has led to the need make difficult decisions as to who should receive blood and who should wait. Beyond the potential for these difficult decisions within each hospital or region, the shortage has impacted the United States and the world unequally raising many ethical questions about how blood should be allocated fairly. An ethical framework is needed to guide these decisions. Speakers will share their perspectives on how should blood be allocated both within hospitals and across nations and how to prioritize patients most in need of blood components during critical blood shortages. Attendees will learn how to create ethical frameworks to guide decision making as well as generate proactive solutions including the development of futility protocols.

Learning Objectives:
  • Describe the current ethical challenges created by the ongoing critical blood shortage.
  • Discuss potential proactive solutions including development of futility protocols to guide transfusion decision making.
  • Create an ethical framework to understand how to triage patient transfusion needs.
Moderator(s): Speaker(s):
  • Dr. Pampee P. Young, MD, PhD, Chief Medical Officer, Biomedical Services, American Red Cross Biomedical Services
  • Lauren Smith, MD, University of Michigan Health System
Disclosures
  • Suzanne Arinsburg, DO : Nothing to Disclose
  • Pampee Young, MD, PhD : Fresenius Kabi: Consultant CTS: Consultant Ortho Diagnostics: Speaker's Bureau Roche: Consultant Eluciderm: Board of Directors
  • Lauren Smith, MD : Bayer: Expert witness

AM22-04-L: Oral Abstract Session- Infectious Disease (Internet Live)

Nov 6, 2022 11:15am ‐ Nov 6, 2022 12:15pm

Identification: AM22-04-L

Credits: None available.

Oral abstract session on Infectious Disease.

Learning Objectives:
  • Assess impact of lowering deferral period to 3 months from one year for multiple donor questions on the rates of donor deferral and positive donor markers, stratified by first time and repeat donor status.
  • Explore novel applications of the monocyte monolayer assay, usually used for identifying clinical significance of red cell alloantibodies, for studying opsonic phagocytosis of both sexual and asexual stages of Plasmodium falciparum.
Speaker(s): Moderator(s):
  • Scott Koepsell, MD PhD, University of Nebraska Medical Center
  • Jed B. Gorlin, MD, MBA, Innovative Blood Resources, division of New York Blood Center

Concurrent Sessions iconConcurrent Sessions

Preview Available

Concurrent Sessions

Nov 6, 2022 11:15am ‐ Nov 6, 2022 12:15pm

Identification: CC-01

Credits: None available.


AM22-05-L: Do More with Less: How to Apply the 80/20 Rule to Quality Assurance (Internet Live)

Nov 6, 2022 1:30pm ‐ Nov 6, 2022 2:30pm

Identification: AM22-05-L

Credits: None available.

Twenty percent of what you do yields eighty percent of the results. How can we ensure quality while dealing with staffing shortages, increased workload per staff member, and other contributing factors? The key is to work smarter and NOT harder! In this presentation you will learn about the 80/20 rule and how it can transform how you spend your time and energy to yield maximum results in the least amount of time. We will discuss how the 80/20 rule can improve quality from both an operations and regulatory affairs perspective. This method has been used by one panel member to increase administrative productivity by an amazing 300%! If you are looking for a way to get more done in less time while ensuring quality and safety then this presentation is for you! While this presentation will mainly focus on the 80/20 rule and quality, the principles and methods are easily extrapolated to other functional and administrative areas.

Learning Objectives:
  • Integrate the 80/20 rule into your quality workload planning process
  • Apply the ABCDE method of time management and prioritization to identify your most important tasks
  • Utilize the 80/20 rule to increase quality assurance efficiency
Speaker(s): Disclosures
  • Edward Griffin, MBA, MS, MLS(ASCP)SBB, CQA(ASQ), PMP : Nothing to Disclose
  • Celia Clifford, MS, MT (ASCP) : Nothing to Disclose

AM22-06-L: Convalescent Plasma: Past, Present, Future (Internet Live)

Nov 6, 2022 1:30pm ‐ Nov 6, 2022 2:30pm

Identification: AM22-06-L

Credits: None available.

Agenda
- Moderator Introductions (Dan Waxman) CCP & EUA for immunosuppressed population (Jonathon Senefeld)
- AABB Guidelines (Aaron Tobian)
- Research implications and considerations for the future (Eric Salazar)
- Lessons learned and blood centers preparation for future pandemics (Bill Block)
- Q&A/Panel Discussion

Learning Objectives:
  • Discuss the current uses of convalescent plasma and existing guidelines.
  • Consider research implications of convalescent plasma in the future.  
  • Describe lessons learned from the COVID-19 pandemic and possible preparations for future pandemics.  
Moderator(s): Speaker(s): Disclosures
  • Dan Waxman, MD : Nothing to Disclose
  • Claudia Cohn, MD, PhD : Nothing to Disclose
  • Jonathon Senefeld, Ph.D : Nothing to Disclose
  • William Block : Nothing to Disclose
  • Eric Salazar, MD, PhD : Regeneron: Local PI

AM22-07-L: Oral Abstract Session- Platelets and Novel Therapeutics (Internet Live)

Nov 6, 2022 1:30pm ‐ Nov 6, 2022 2:30pm

Identification: AM22-07-L

Credits: None available.

This is an oral abstract session about Platelets and Novel Therapeutics.

Learning Objectives:
  • Consider an innovative therapeutic agent that could be useful for the treatment of all immune cytopenias
  • Discuss a potential novel therapy for IgG-mediated hemolysis
  • Examine the alloantibody response to platelet transfusions and platelet rich plasma
Moderator(s): Speaker(s):

Concurrent Sessions iconConcurrent Sessions

Preview Available

Concurrent Sessions

Nov 6, 2022 1:30pm ‐ Nov 6, 2022 2:30pm

Identification: CC-02

Credits: None available.


AM22-08-L: Plenary Abstract Session (Internet Live)

Nov 6, 2022 2:45pm ‐ Nov 6, 2022 4:15pm

Identification: AM22-08-L

Credits: None available.

Oral abstract session on Plenary Abstracts.

Learning Objectives:
  • Understand the impact of pathogen reduction on platelet transfusion safety.
  • Evaluate the risk of transfusion-transmitted SARS-CoV-2.
  • Examine the mechanism of alloantibody production after platelet transfusions.
  • Investigate the use of platelets as a method deliver therapeutic proteins.
  • Understand the mechanism underlying the Helgeson phenotype, the serological null phenotype of the Knops blood group system.
Moderator(s): Speaker(s):

AM22-09-L: Managing the Apheresis Center: How Do We Produce Enough Products for the Ever-Increasing Demand? (Internet Live)

Nov 7, 2022 10:00am ‐ Nov 7, 2022 11:00am

Identification: AM22-09-L

Credits: None available.

Novel biotherapies are often driven by industrial innovations but require clinical and academic medical collaborations. In the evolving fields of biotherapies and transfusion medicine, there is an ever-increasing demand for high quality products as raw materials for further manufacturing. An important challenge for apheresis centers is management of distinct industrial protocol details, including heterogenous operational parameters that may not always conform to routine clinical practices. Factors such adequate staffing, budget, equipment, space and shipping and delivering logistics pose formidable challenges to blood centers and hospitals and threaten the ability of these organizations to meet demand. This session will discuss real experiences from professionals in the field and will propose creative approaches in overcoming those challenges, including the business agreements as well as the regulatory framework involving these type of products. We will engage the audience to map out the goals of their own apheresis production pipelines by applying principles of process improvement that identify and then leverage their operational constraints, with concrete examples. The speakers will also share practical tips regarding the establishment of business agreements that include negotiations between the sponsor(s) and the institution.

Learning Objectives:
  • Describe the process of setting up and managing an apheresis center that can provide high quality products for cellular therapy, particularly in the setting of clinical trials using experimental therapies.
  • Discuss how the theory of constraints can be applied to your apheresis center to identify and manage bottlenecks
  • Review the regulatory framework around cellular therapy products
  • Recommend the minimal elements of business agreements between institutions and the sponsors or manufacturing biopharma companies that need to be present before signatures are obtained.
Speaker(s): Disclosures
  • Federico Rodriguez Quezada, SBB, MLS(ASCP) : Nothing to Disclose
  • Patricia Brunker, MD DPhil : Safi Biosystems: Advisory Board, Consultant